Cellectis SA (CLLS)
1.43
+0.03
(+2.14%)
USD |
NASDAQ |
Oct 02, 16:00
1.41
-0.02
(-1.40%)
After-Hours: 20:00
Cellectis Net Income (Quarterly) : -21.79M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.79M |
| March 31, 2026 | -17.83M |
| December 31, 2025 | -26.30M |
| September 30, 2025 | 0.5863M |
| June 30, 2025 | -24.05M |
| March 31, 2025 | -18.13M |
| December 31, 2024 | 5.88M |
| September 30, 2024 | -23.06M |
| June 30, 2024 | -25.27M |
| March 31, 2024 | 5.643M |
| December 31, 2023 | -63.62M |
| September 30, 2023 | -17.48M |
| June 30, 2023 | -29.69M |
| March 31, 2023 | -27.83M |
| December 31, 2022 | -25.70M |
| September 30, 2022 | -25.40M |
| June 30, 2022 | -18.86M |
| March 31, 2022 | -28.24M |
| December 31, 2021 | -28.08M |
| September 30, 2021 | -40.07M |
| June 30, 2021 | -41.61M |
| March 31, 2021 | -15.35M |
| December 31, 2020 | -45.49M |
| Date | Value |
|---|---|
| September 30, 2020 | -33.60M |
| June 30, 2020 | -35.85M |
| March 31, 2020 | 16.60M |
| December 31, 2019 | -41.16M |
| September 30, 2019 | -19.48M |
| June 30, 2019 | -36.64M |
| March 31, 2019 | -17.72M |
| December 31, 2018 | -26.06M |
| September 30, 2018 | -25.31M |
| June 30, 2018 | -9.738M |
| March 31, 2018 | -27.04M |
| December 31, 2017 | -28.72M |
| September 30, 2017 | -30.92M |
| June 30, 2017 | -26.50M |
| March 31, 2017 | -21.07M |
| December 31, 2016 | -13.44M |
| September 30, 2016 | -15.69M |
| June 30, 2016 | -7.063M |
| March 31, 2016 | -32.48M |
| December 31, 2015 | 9.021M |
| September 30, 2015 | -14.19M |
| June 30, 2015 | -24.52M |
| March 31, 2015 | 7.100M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| DBV Technologies SA | -- |
| Akari Therapeutics Plc | -4.816M |
| Autolus Therapeutics Plc | -39.18M |
| Evaxion AS | -3.724M |
| Bicycle Therapeutics Plc | -50.42M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 5.222M |
| Total Expenses (Quarterly) | 27.01M |
| EPS Diluted (Quarterly) | -0.2165 |
| Enterprise Value | 81.43M |
| Gross Profit Margin (Quarterly) | 15.62% |
| Profit Margin (Quarterly) | -417.3% |
| Earnings Yield | -45.47% |
| Normalized Earnings Yield | -41.86 |